Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies
Cystic fibrosis (CF) is a genetic disease that affects the exocrine glands and is caused by cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations. Lung disease is the leading cause of morbidity in patients. Target-specific treatment of CF has been achieved using monoclonal antibo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S131901642200250X |
| _version_ | 1828088592416636928 |
|---|---|
| author | Sivakumar S. Moni Asmaa Al Basheer |
| author_facet | Sivakumar S. Moni Asmaa Al Basheer |
| author_sort | Sivakumar S. Moni |
| collection | DOAJ |
| description | Cystic fibrosis (CF) is a genetic disease that affects the exocrine glands and is caused by cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations. Lung disease is the leading cause of morbidity in patients. Target-specific treatment of CF has been achieved using monoclonal antibodies (mAbs). The purpose of this article is to discuss the possibility of treating CF with mAbs through their significant target specificity. We searched electronic databases in Web of Science, PubMed, EMBASE, Scopus, and Google Scholar from 1984 to 2021. We discussed the critical role of targeted therapy in cystic fibrosis, as it will be more effective at suppressing the molecular networks. After conducting a critical review of the available literature, we concluded that it is critical to understand the fundamental molecular mechanisms underlying CF prior to incorporating biologics into the therapy regimen. Omalizumab, Mepolizumab, Benralizumab, Dupilumab and KB001-A have been successfully screened for asthma-complicated CF, and their efficacies have been well reported. Despite the availability of effective targeted biologics, treating CF has remained a difficult task, particularly when it comes to reduction of secondary inflammatory mediators. This review emphasizes the overall views on CF, the immunological mechanism of CF, and the prospective therapeutic use of mAbs as potential targeted biologics for enhancing the overall status of human health. |
| first_indexed | 2024-04-11T05:27:52Z |
| format | Article |
| id | doaj.art-15a2d7b6408146bc9215db7bacfb5c75 |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-04-11T05:27:52Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-15a2d7b6408146bc9215db7bacfb5c752022-12-23T04:39:58ZengElsevierSaudi Pharmaceutical Journal1319-01642022-12-01301217361747Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodiesSivakumar S. Moni0Asmaa Al Basheer1Corresponding author.; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaCystic fibrosis (CF) is a genetic disease that affects the exocrine glands and is caused by cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations. Lung disease is the leading cause of morbidity in patients. Target-specific treatment of CF has been achieved using monoclonal antibodies (mAbs). The purpose of this article is to discuss the possibility of treating CF with mAbs through their significant target specificity. We searched electronic databases in Web of Science, PubMed, EMBASE, Scopus, and Google Scholar from 1984 to 2021. We discussed the critical role of targeted therapy in cystic fibrosis, as it will be more effective at suppressing the molecular networks. After conducting a critical review of the available literature, we concluded that it is critical to understand the fundamental molecular mechanisms underlying CF prior to incorporating biologics into the therapy regimen. Omalizumab, Mepolizumab, Benralizumab, Dupilumab and KB001-A have been successfully screened for asthma-complicated CF, and their efficacies have been well reported. Despite the availability of effective targeted biologics, treating CF has remained a difficult task, particularly when it comes to reduction of secondary inflammatory mediators. This review emphasizes the overall views on CF, the immunological mechanism of CF, and the prospective therapeutic use of mAbs as potential targeted biologics for enhancing the overall status of human health.http://www.sciencedirect.com/science/article/pii/S131901642200250XCystic fibrosisMolecular targetsTarget-specificMonoclonal antibodiesTherapeutic implementation |
| spellingShingle | Sivakumar S. Moni Asmaa Al Basheer Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies Saudi Pharmaceutical Journal Cystic fibrosis Molecular targets Target-specific Monoclonal antibodies Therapeutic implementation |
| title | Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| title_full | Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| title_fullStr | Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| title_full_unstemmed | Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| title_short | Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| title_sort | molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies |
| topic | Cystic fibrosis Molecular targets Target-specific Monoclonal antibodies Therapeutic implementation |
| url | http://www.sciencedirect.com/science/article/pii/S131901642200250X |
| work_keys_str_mv | AT sivakumarsmoni moleculartargetsforcysticfibrosisandtherapeuticpotentialofmonoclonalantibodies AT asmaaalbasheer moleculartargetsforcysticfibrosisandtherapeuticpotentialofmonoclonalantibodies |